John Kelly
Analyst · William Blair
Thank you, Mark, and good afternoon, everyone. Before I begin, please note that I will be discussing non-GAAP financial measures, such as EBITDA, adjusted EBITDA, adjusted net income, adjusted EPS, and free cash flow. Our press release, 10-Q, and Investor Relations page on the Huron website have reconciliations of these non-GAAP measures to the most comparable GAAP measures, along with the discussion of why management uses these non-GAAP measures and why management believes they provide useful information to investors regarding our financial condition and operating results. Before discussing our financial results for the quarter, I would like to discuss 1 housekeeping item: our Healthcare segment results do include a full quarter of operating results from our acquisition of RelateCare which closed in June of this year. Now I'll share some of the key financial results for the third quarter. Third quarter of 2026 produced record RBR of $482.5 million, up 11.6% from $432.4 million in the same quarter of 2025. The increase in RBR for the quarter was driven by growth across all 3 operating segments, a double-digit percentage growth in both our Consulting and Managed Services and our Digital capabilities. Net income for the third quarter of 2026 was $28.4 million or $1.75 per diluted share compared to net income of $30.4 million or $1.71 per diluted share in the third quarter of 2025. As a percentage of total revenues, net income decreased to 5.8% in the third quarter of 2026, and compared to 6.9% in the third quarter of 2025. Diluted earnings per share in the third quarter of 2026 reflects noncash credit loss recognized on our convertible debt investment in a third party, which had a $0.36 unfavorable impact on diluted earnings per share for the quarter. Our effective tax rate in the third quarter of 2026 was 32.9%, which is less favorable than the statutory rate, inclusive of state income taxes, primarily due to certain nondeductible expense items and the inability to recognize tax benefits related to the credit loss recognized on our convertible debt investment in the third party. We now expect a full year effective tax rate between 27% and 29%. Adjusted EBITDA was $77.3 million in Q3 2026 or 16% of RBR compared to $67.4 million in Q3 2025, or 15.6% of RBR. The 16% adjusted EBITDA margin is our highest quarterly adjusted EBITDA margin in the last 8 years. Increase in adjusted EBITDA was primarily attributable to increases in Healthcare and Education segment operating income, excluding the impact of segment depreciation and amortization and segment restructuring charges, partially offset by an increase in certain unallocated corporate expenses. The increase in adjusted EBITDA margin to 16% from 15.6% and in the prior year period is reflective of an increase in Education segment operating income margin, scaling of our unallocated SG&A expenses. Adjusted net income was $42.6 million or $2.62 per diluted share in Q3 2026 compared to $37.4 million or $2.10 per diluted share in the third quarter of 2025, growing adjusted diluted earnings per share by 24.8% year-over-year. Now I'll discuss the performance of each of our operating segments. The Healthcare segment generated 53% of total company RBR during the third quarter of 2026. Segment posted record RBR of $255.8 million, up $36.2 million or 16.5% from the third quarter of 2025, driven by strong demand for our Managed Services, performance improvement, financial advisory and Digital offerings as well as incremental RBR from our acquisitions. RBR in the third quarter of 2026 included $16.7 million from our acquisitions of RelateCare and [ AXIOM. ] Operating income margin for the Healthcare segment was 30.5% in Q3 2026 compared to 30.9% in Q3 2025. Slight decrease in segment operating income margin was primarily driven by an increase in total compensation expense as a percentage of RBR and includes the impact of the integration of RelateCare into our business. We have maintained strong margin performance in 2025 and into the first 9 months of 2026, reflective of the highly disciplined execution delivered by our Healthcare team. The Education segment generated 29% of total company RBR during the third quarter of 2026. Education segment RBR in the third quarter of 2026 was $138 million, up $8.6 million or 6.6% compared to the third quarter of 2025. The increase in RBR was entirely organic and driven by strong demand for our Digital and Managed Services offerings. The operating income margin for Education increased to 29.1% for Q3 2026 compared to 25.7% for the third quarter of 2025. The increase was primarily driven by revenue growth that outpaced the increase in salaries and related expenses for our revenue-generating professionals and decreases in salaries and related expenses for our support personnel and technology costs. The Commercial segment generated 18% of total company RBR during the third quarter of 2026. Commercial segment RBR was $88.8 million in Q3 2026, up $5.4 million or 6.4% from the third quarter of 2025. The increase in RBR reflects $4.3 million of incremental RBR primarily from our acquisition of Wilson Perumal, as well as strong demand for our strategy offerings. Operating income margin for the Commercial segment was 13.9% for Q3 2026 compared to 16.4% in the same quarter in 2025. The decrease was primarily driven by increases in performance bonus expenses, reflecting increased full year performance expectations for certain teams within the segment. In addition to the increase in performance bonus expense, the decline in margin also reflects continued investment in key business development, leadership, and delivery talent that we expect to drive above company average growth in 2027. These growth-oriented investments totaled $2.2 million or 2.5% of segment RBR for Q4 (sic) [ Q3 ]. Corporate expenses not allocated at the segment level, excluding restructuring charges, were $58.7 million in Q3 2026 compared to $56.5 million in Q3 2025. Unallocated corporate expenses in the third quarter of 2026, included income of $200,000 compared to expense of $2.7 million in Q3 2025 related to the changes in the liability of our deferred compensation plan, which are offset by the change in fair value of the investment assets used to fund that plan reflected in other income. Excluding the impact of the deferred compensation plan in both periods, unallocated corporate expenses increased approximately $5.1 million, primarily driven by increases in compensation costs for our support personnel, software and data hosting expenses, partially offset by a decrease in legal expenses. Now turning to the balance sheet and cash flows. DSO came in at 83 days for the third quarter of 2026 compared to 79 days in the second quarter of 2026. The increase when compared to the second quarter of 2026, is primarily attributable to the impact of collections on certain Healthcare projects in alignment with the contractual payment schedules. Cash flow from operations in the third quarter of 2026 was $57 million compared to $93.8 million in the prior year period. During the third quarter of 2026, we used $7.9 million to invest in capital expenditures, inclusive of internally developed software costs, resulting in free cash flow of $49.1 million. We now expect full year free cash flow to be in a range of $150 million to $170 million. Net cash taxes and interest and excluding noncash stock compensation. This update primarily reflects the timing of collections, including a revised payment schedule on a specific multiyear engagement and a higher mix of performance improvement projects with performance-based fee elements within our Healthcare segment during 2026. We expect to collect working capital related to such projects in 2027 in accordance with our contractual terms. Our leverage ratio as defined in our senior bank agreement, was 2.6x adjusted EBITDA as of September 30, 2026 compared to 2.8x as of June 30, 2026. We remain confident that we are on track to achieving a leverage ratio between 2x and 2.5x by the end of 2026, in alignment with the capital allocation strategy outlined in our most recent Investor Day. Total debt as of September 30, 2026, was $815 million, consisting entirely of our senior bank debt. We finished the quarter with cash of $25.6 million for net debt of $789.4 million. This was a $13.4 million decrease in net debt compared to Q2 2026, which incorporates the share repurchases made during the quarter. In the third quarter of 2026, we used $26.3 million to repurchase approximately 173,000 shares bringing our total year-to-date repurchases to $234.9 million or approximately 1.7 million shares, reflecting an average repurchase price of $136 per share. Year-to-date repurchases represent 10% of our common stock outstanding as of December 31, 2025. As of October 31, 2026, $255.9 million remained available for share repurchases, inclusive of the $200 million increase authorized by our Board of Directors in October 2026. Finally, let me turn to our guidance for full year 2026. As Mark mentioned, today, we are updating our annual guidance by narrowing our RBR guidance to a range of $1.855 billion to $1.885 billion, affirming our adjusted EBITDA guidance range of 14.5% to 15%, and increasing and narrowing our adjusted non-GAAP EPS to a range of $9.20 to $9.40. Thanks, everyone. I would now like to open the call to questions. Operator?